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ABBREVIATIONS:
APC – antigen presenting cell
AREG – amphiregulin
ATP – adenosine triphosphate
CD – Crohn’s disease
CDAI – Crohn’s disease activity index
CTLA-4 – cytotoxic T lymphocyte antigen 4
DC – dendritic cell
DR5 – death receptor 5
DSS – dextran sulfate sodium
Ebi3 – Epstein Barr virus induced 3
EGF – epidermal growth factor
FACS – fluorescence-activated cell sorting
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Fgl2 – fibrinogen-like protein 2
Foxp3 – Forkhead box P-3
GALT – gut-associated lymphoid tissue
GC-MS – gas chromatography mass spectometry
GI – gastrointestinal
GMP – good manufacturing practice
GvHD – graft versus host disease
HEPA – high efficiency particulate air 
HSCT – haematopoetic stem cell transplant
IBD – inflammatory bowel disease
IFNγ – interferon γ
IL – interleukin
IPEX – ‘immune dysregulation, polyendocrinopathy, enteropathy, X-linked’
LPMC – lamina propria mononuclear cell
MACS – magnetic bead-activated cell sorting
MAdCAM-1 – mucosal vascular addressin cell adhesion molecule 1
MHC – major histocompatibility complex
MMP – matrix metalloproteinase
NK – natural killer
NOD – non-obese diabetic 
PBMC – peripheral blood mononuclear cell
RARα – retinoic acid receptor α
RORC – related orphan receptor C
RPMI – Roswell Park Memorial Institute
SCID – severe combined immunodeficiency
SLE – systemic lupus erythematosus
STAT – signal transducer and activator of transcription
T1DM – type 1 diabetes mellitus
TCR – T cell receptor
Teff – effector T cell
TGF-β – transforming growth factor β
Th1 – T helper 1 cell
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Th17 – T helper 17 cell
TIGIT – T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based 
inhibitory motif (ITIM) domains
TNBS – 2,4,6-trinitrobenzene sulfonic acid
TNFα – tumour necrosis factor α
TRAIL – tumour necrosis factor-related apoptosis inducing ligand
Treg – regulatory T cell
pTreg – peripheral regulatory T cell
tTreg – thymic regulatory T cell
UC – ulcerative colitis
ABSTRACT:
The prevalence of inflammatory bowel disease is rising in the Western world. Despite an 
increasing repertoire of therapeutic targets, a significant proportion of patients suffer 
chronic morbidity. Studies in mice and humans have highlighted the critical role of 
regulatory T cells in immune homeostasis, with defects in number and suppressive function 
of regulatory T cells seen in Crohn’s disease patients. We review the function of regulatory T 
cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We 
explore the principles and challenges of manufacturing a cell therapy, and discuss clinical 
trial evidence to date for their safety and efficacy in human disease, with particular focus on 
the development of a regulatory T cell therapy for Crohn’s disease. 
Keywords: Crohn’s disease, Immunology, Immunoregulation, Intestinal T cell, T lymphocytes
INTRODUCTION:
Inflammatory bowel disease (IBD), chiefly comprising Crohn’s disease (CD) and ulcerative 
colitis (UC), is a chronic inflammatory group of disorders of the gastrointestinal (GI) tract 
arising from overexuberant innate and adaptive immune responses to environmental 
factors in genetically susceptible individuals. IBD affects at least 0.5% of the population in 
the Western world with 1 million sufferers in USA and 2.5 million in Europe.1 Global 
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prevalence continues to increase, largely driven by rising numbers of patients in newly 
industrialised regions including India and Asia.1 The burden of disease is significant with 20-
25% of patients experiencing chronic continuous symptoms which contributes to higher 
rates of unemployment, sick leave and permanent work disability.2 Even with an aggressive 
top-down approach to therapy, the majority of patients fail to achieve prolonged, steroid-
free remission and are at particular risk of requiring surgical intervention. Cumulative 
surgery rates in CD are high in Europe with 30-50% of patients requiring surgical 
intervention and up to 20% needing a reoperation 5-10 years from diagnosis.2
As our understanding of the pathophysiology of IBD and its socioeconomic impact has 
evolved, there has been great impetus to identify novel therapeutic targets to add to the 
existing arsenal of immunomodulators and biologics. These have focussed on a variety of 
areas including targeting lymphocyte trafficking (vedolizumab, ozanimod, anti-MAdCAM1) 
and activation (anti-IL6, anti-IL12/IL23), modulating intestinal barrier function 
(phosphatidylcholine), matrix remodelling (STNM-01, MMP9 blocker) and manipulation of 
gut microbiota (faecal microbiota transplant).3 An important pathological process 
increasingly recognised as driving intestinal inflammation and autoimmunity is the loss of 
immune homeostasis secondary to qualitative or quantitative defects in the regulatory T cell 
(Treg) pool.
Tregs are CD4+ T cells that characteristically express the high affinity IL-2 receptor -chain 
(CD25), and master transcription factor Forkhead box P-3 (Foxp3), which is essential for 
their suppressive phenotype and stability.4–6 As activated CD4+ T cells can upregulate CD25 
expression, an additional defining feature of Tregs is the absence of IL-7 receptor -chain 
(CD127).7 Their primary function is as dominant controllers of self-tolerance, tissue 
inflammation and long-term immune homeostasis. Despite making up only 5-10% of the 
peripheral CD4+ T cell pool, Tregs exert powerful inhibitory effects on effector cells through 
a variety of mechanisms including cytokine secretion, metabolic disruption, inhibition of 
dendritic cells (DCs) and cytolysis. These mechanisms have been rigorously examined using 
animal models and shown to protect against the development of intestinal inflammation. 
Studies in patients with IBD have identified defects in the number and distribution of Tregs, 
and their ability to traffic to the GI tract.8 Additionally, resistance to Treg-mediated 
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suppression has been noted in lamina propria T effector cells (Teffs).9 These factors are 
likely to be pivotal in driving intestinal inflammation.
There is growing interest in the therapeutic potential of adoptively transferring healthy 
Tregs into patients with a wide range of conditions, including IBD and autoimmune disease, 
in an attempt to shift the balance in areas of active inflammation towards a more 
tolerogenic microenvironment. Early phase clinical trials have already reported in the fields 
of solid organ transplantation, graft-versus-host disease (GvHD) and type 1 diabetes mellitus 
(T1DM) with reassuring safety data and potential signals of efficacy. 
This review provides a summary of the suppressive mechanisms utilised by Tregs and 
highlights seminal work linking intestinal inflammation with loss of Treg function in both 
animal models of disease and in humans. Additionally, we review ongoing clinical trials with 
Treg therapy and outline an entirely novel therapeutic strategy for CD using Tregs expanded 
under GMP (Good Manufacturing Practice) conditions that will be adoptively transferred to 
patients in an attempt to ameliorate intestinal inflammation and restore immune 
homeostasis.
TREGS IN HEALTH AND DISEASE:
Tregs can be broadly divided into two groups, thymic Tregs (tTregs) or peripherally induced 
Tregs (pTregs) based on their developmental origin. Tregs generated in the thymus (tTregs) 
in the early neonatal period migrate to peripheral organs where they maintain tolerance. 
This was discovered in 1969 by Nishizuka and Sakakura who showed that in mice, 
thymectomy 3 days after birth led to the depletion of Foxp3+ Tregs and development of 
autoimmune oophoritis.10 In contrast, mice who had thymectomy at day 7 remained healthy 
as the tTregs had already migrated to the periphery by this point.11 Over a decade later, 
Sakaguchi et al demonstrated that day-3 thymectomy autoimmune oophoritis could be 
prevented with CD4+ T cell inoculation from healthy syngeneic donors. Conversely, the 
adoptive transfer of T cells from these sick mice were capable of inducing autoimmune 
disease in healthy T cell deficient mice.12 Similar findings were noted in rats that underwent 
adult thymectomy and irradiation resulting in lymphopenia, autoimmune diabetes and 
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insulitis. An injection of CD45RC(low) T cells from healthy donors were capable of 
preventing disease.13 Mottet et al subsequently described CD25-expressing CD4+ T cells that 
were able to cure established T cell transfer colitis.14 By the early 2000’s it was clear that a 
thymically-derived CD4+CD25+ T cell population possessed the ability to suppress 
autoreactive T cells and eliminate autoimmunity.  
Peripherally induced Tregs (pTregs) were first described in 2003 where naïve CD4+CD25- T 
cells could be converted into Foxp3-expressing CD4+CD25+ Tregs by T cell receptor (TCR) co-
stimulation in the presence of TGF-β.15 pTreg conversion in gut-associated lymphoid tissues 
(GALT) was enhanced when naïve CD4+ T cells encountered antigen in the presence of TGF-
β, IL-2 and retinoic acid (RA).16,17 This is facilitated by CD103+ DCs conditioned by the 
intestinal microenvironment to produce or activate TGF-β and provide RA.18,19 In the 
absence of CD103 expression, DCs fail to induce Treg development and produce 
proinflammatory cytokines.18,20 Additionally, in patients with UC, CD103+ DCs appear to 
have impaired ability to generate pTregs, but induce colitogenic T helper (Th) 1, Th2 and 
Th17 responses suggesting CD103+ DC-mediated pTreg induction is functionally relevant in 
IBD pathogenesis.21 
Distinguishing tTregs from pTregs can be difficult as no definitive markers exist. Recently, 
the expression of the membrane protein neuropilin-1 (Nrp1) and the transcription factor 
Helios by tTregs but not by pTregs has been used to differentiate Treg subsets.22 The 
significance of this lies in the epigenetic differences in the Foxp3 locus rendering pTregs less 
stable and more likely to demonstrate plasticity towards a Th17 cell phenotype under 
inflammatory conditions.23 The developmental origin of Tregs selected for expansion as a 
cell therapy product is therefore an important consideration and will be addressed in more 
detail later in this review.
The first study identifying Tregs in humans was published in 2001. Baecher-Allan et al 
characterised CD4+CD25+ T cells in the thymus and peripheral blood which exhibited anti-
inflammatory and suppressive properties.24 Subsequent work established Foxp3 as the 
master transcription factor for Tregs.4,6,25 Foxp3 can however be expressed transiently in 
non-regulatory CD4+ T cells upon TCR activation and the CD4+CD25+CD127lo surface 
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7
phenotype must be used to define Tregs.26 Inactivating mutations in Foxp3 clinically 
manifest as severe autoimmunity with a scurfy phenotype in mice and IPEX syndrome 
(‘immune dysregulation, polyendocrinopathy, enteropathy, X-linked’) in humans.27–30 With 
autoimmune enteropathy (manifesting as chronic diarrhoea and malabsorption) a 
predominant feature, attention was focussed on the functional role of Tregs within the GI 
tract. 
Peripheral Tregs are found in abundance in the intestinal lamina propria where interactions 
with environmental antigens can shape phenotypic differences and transcription factor 
expression.31 The gut microbiota represents a substantial antigen load driving the expansion 
of colonic pTregs that co-express the Th17 master transcription factor RORt.32 These 
Foxp3+ RORt+ pTregs have a stable regulatory phenotype and provide tolerance against the 
gut microbiota.33,34 Conversely, RORt- pTregs are found in the small intestine where they 
are induced by dietary antigens and repress underlying Th1 cell responses to ingested 
proteins.35 Finally, an intestinal tTreg population that co-express the Th2 master 
transcription factor, GATA3, has been shown to mediate repair of the intestinal mucosa. 
GATA3+ tTregs express high levels of the IL-33 receptor, ST2, and amphiregulin, an 
epidermal growth factor receptor ligand involved in tissue repair.36,37 
Following on from the fundamental observations linking Treg dysfunction to an array of 
autoimmune polyendocrine syndromes, studies began to emerge identifying defects in 
either number or function of peripheral blood Tregs in autoimmune disorders including IBD, 
type 1 diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis 
and rheumatoid arthritis.8,38–42 Maul et al observed that in patients with active IBD, the 
intestinal lamina propria Treg pool was significantly smaller than that of a positive control, 
namely diverticulitis.8 Additionally, in these patients, the peripheral blood Treg pool was 
smaller than that of inactive IBD or diverticulitis.8 Interestingly, the peripheral blood Tregs 
retained their suppressive capacity suggesting that disease may be driven by ineffective 
trafficking to the gut and reduced numbers of Tregs. Furthermore, colitogenic T cells from 
IBD patients appear to be resistant to TGF-β1-mediated Treg suppression highlighting an 
additional defect in immunological tolerance that may drive disease.43
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8
TREG FUNCTION AND COLITIS:
Tregs function as key mediators of peripheral tolerance through direct cellular contact and 
paracrine actions on tissues where they reside.44,45 It is essential that Tregs effectively traffic 
to target organs where they promote a tolerogenic microenvironment. An important 
example is IL-10-secreting Tregs that reside in the GI mucosa and control inflammatory 
responses induced by environmental insults. Selective disruption of IL-10 expression in 
these Tregs has been shown to cause spontaneous colitis.46 This is one of many modalities 
that Tregs can employ to maintain immune homeostasis at the mucosal interface. Others 
include inhibitory cytokine secretion, cytolysis of effector cells, metabolic disruption, 
neutralization of antigen presenting cells (APC) and promotion of tissue repair.47 These 
functions will be reviewed in further detail outlining their associations with intestinal 
inflammation (see Figure 1).
Inhibitory Cytokines:
The Treg cytokine repertoire includes the anti-inflammatory molecules IL-10, TGF-β and IL-
35. The expression of IL-10 and IL-35 requires TCR signalling, suggesting that Treg function in 
part relies on antigen encounter in the local microenvironment.48 Pioneering work by 
Powrie et al over 20 years ago showcased the potent inhibitory ability of IL-10, where 
recombinant IL-10 therapy ameliorated established T cell transfer colitis.49 Subsequently, 
the co-transfer of CD45RB(low) T cells were shown to prevent colitis and IL-10 was 
identified as an essential mediator for this in vivo suppression.50 The suppressive effects of 
Treg-derived IL-10 in mice appear to be specific for mucosal surfaces rather than controlling 
systemic autoimmunity.46 Further studies have demonstrated that IL-10 induces robust 
activation of a STAT3-dependent Th17 suppression program in Tregs, downstream of IL-
10R.51 This suppresses pathogenic Th17 cell responses and ablation of IL-10R in Tregs has 
been shown to cause colitis. It is therefore plausible that disordered IL-10 signalling may 
contribute to aberrant Th17 activity, which is implicated in IBD.52 In fact, there have been 
several cases of homozygous loss-of-function mutations in Il-10 and Il-10r arising in 
individuals from consanguineous marriages. These resulted in infantile severe, progressive, 
intractable Crohn’s-like colitis.53
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9
TGF-β plays an important role inducing pTreg formation upon antigen encounter in GALT 
and has a functional role in suppressing pro-inflammatory pathways.54 Tregs are capable of 
producing TGF-β, which profoundly suppresses the proliferation of Teffs.55 Treg-derived 
TGF-β1 inhibits Th1-cell differentiation and IBD in a transfer model of colitis.56 Conversely, 
Tregs from TGF-β1-deficient mice fail to suppress intestinal inflammation in a SCID transfer 
model of colitis.55 Human studies have supported these early findings; a study on healthy 
human colonic biopsies and lamina propria mononuclear cells (LPMC) treated with anti-TGF-
β neutralising antibody showed that TGF-β is a critical suppressor of T-bet-dependent Teff 
proliferation and Th1 cytokine expression.57 This suggests a role for TGF-β in suppressing 
intestinal inflammation in humans. Indeed, MacDonald et al have shown that colonic tissue 
and isolated T cells from patients with CD overexpress Smad7, an inhibitor of TGF-β1 
signalling.58 Furthermore, colonic LPMCs from CD patients were resistant to Treg-mediated 
suppression, a phenomenon that could be reversed with Smad7 antisense treatment.43 
Smad 7 antisense therapy (Mongersen) was subsequently evaluated in CD but, despite 
promising early phase data, a phase III clinical trial was terminated early due to lack of 
benefit.59,60 Although Mongersen may overcome Teff resistance to TGF-β, it is possible in CD 
there are insufficient numbers of functional Tregs in the mucosal environment to produce 
TGF-β explaining the disappointing trial outcome .
IL-35 is a heterodimer of Ebi3 and IL-12 that is constitutively expressed in Foxp3+ Tregs but 
not Teffs. It was first described in 2007 where Ebi3-/- and IL-12 -/- Tregs were shown to have 
significantly reduced regulatory activity in vitro and failed to cure T cell transfer colitis in 
vivo.61 Additionally, IL-35 can induce the generation of a regulatory population from naïve 
mouse or human CD4+ T cells. These so-called iT(R)35 cells mediate suppression via IL-35 
alone, do not express Foxp3, and are strongly suppressive and stable in vivo.62 In both 
dextran sulphate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis, 
recombinant IL-35 therapy can treat disease through downregulation of the Th1 and Th17 
master transcription factors, T-bet and RORC, respectively, and through inhibition of IFN-, 
IL-6 and IL-17.63 
Inhibition of Metabolic Processes:
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10
While Tregs are not known to produce IL-2, their development and function is critically 
dependent on this cytokine. IL-2 and the transcription factor STAT5, downstream of IL-2 
receptor (IL-2R), induce the expression of Foxp3 and differentiation of tTregs.64 
Furthermore, STAT5 activation driven by IL2R signalling enhances the suppressor function of 
differentiated Tregs.65 An absence of IL-2 signalling has been shown to reduce the number 
and functional activity of Tregs, predisposing to autoimmunity and inflammation.66,67 The 
structural conformation of IL-2R in Tregs provides a competitive advantage for IL-2-receptor 
engagement over alternative cell subsets. Tregs abundantly express IL-2 receptor -chain 
(CD25), which together with the common -chain (c, CD132) and IL-2 receptor -chain 
(CD122) form a characteristic three subunit receptor configuration. This confers a ~1000-
fold increase in receptor affinity for IL-2 over Teffs.68 In a pro-inflammatory environment 
dominated by actively dividing effector cells, Tregs have the ability to “consume” local IL-2, 
starving effector cells of this essential cytokine for survival and proliferation.45,69 Moreover, 
this mechanism has been shown to induce the apoptosis of effector cells.70 This highlights 
an important TCR-independent paracrine mode of suppression in local tissues, facilitated 
through the constitutive expression of high affinity IL-2R (containing CD25). There have 
been a handful of cases of CD25 deficiency in humans often manifesting in an IPEX-like 
syndrome.71–73 A notable case who presented with autoimmune enteropathy at 6 months 
had Foxp3+ Tregs with defective IL-10 expression suggesting that IL-2 responsiveness is 
important for Treg-mediated IL-10 production.74
Tregs can also interfere with adenosine triphosphate (ATP) metabolism to dampen pro-
inflammatory responses. Tregs co-express the ectoenzymes CD39 and CD73 responsible for 
the degradation of ATP and generation of pericellular adenosine.75 Adenosine stimulates the 
A2A receptor on Teffs exerting potent inhibitory effects. Activation of the A2A receptor also 
inhibits IL-6 expression while enhancing the production of TGF-.76 This promotes the 
development of adaptive induced Tregs and simultaneously inhibits pro-inflammatory Th17 
cell formation. Furthermore, signalling through the A2A receptor appears to control in vivo 
murine colitis.77 
Neutralisation of Dendritic Cell Function:
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The activation of T cells requires TCR-antigen/MHC engagement in the context of a 
secondary signal, namely T cell-derived CD28 binding the DC B7 ligands, CD80 and CD86. 
This process is negatively regulated through the production of cytotoxic T lymphocyte 
antigen 4 (CTLA-4) which is constitutively expressed in Foxp3+ Tregs.78 CTLA-4-expressing 
cells can capture CD80 and CD86 by a process of trans-endocytosis and degrade these 
ligands, resulting in impaired co-stimulation via CD28.79 This is a functionally significant 
process with Treg-conditioned DCs inducing poor T cell proliferation.80 An additional 
mechanism mediated through the interaction of CTLA-4 and CD80/CD86 is the upregulation 
of indoleamine 2, 3-deoxygenase in DCs. This is a potent regulatory molecule which 
catabolises the essential amino acid tryptophan to the pro-apoptotic metabolite kynurenine 
leading to suppression of Teff function.64 In vivo models have demonstrated that CTLA-4 is 
essential in preventing autoimmunity. Selective deletion of CTLA-4 in Tregs of BALB/c mice 
results in fatal T cell mediated autoimmune disease at just 20 days of age.81 Additionally, 
several cases of germline heterozygous mutations in CTLA-4 have been identified in 
humans.82 CTLA-4 haploinsufficiency resulted in dysregulation of Tregs, hyperactivation of 
Teffs and lymphocytic infiltration of target organs including the GI tract. It was recently 
discovered that LRBA (lipopolysaccharide-responsive and beige-like anchor protein) 
regulates CTLA-4 expression, where mutations in LRBA lead to reduced levels of CTLA-4.83 
These mutations are commonly associated with primary immunodeficiency, reduced Treg 
numbers and susceptibility to IBD.84,85  
Recently, the coinhibitory molecule TIGIT has been described as an inhibitor of autoimmune 
responses through its interactions with DCs and T cells. TIGIT interacts with its ligand CD155 
on DCs to induce IL-10 and suppress IL-12 production, thereby inhibiting Th1 responses.86 As 
Tregs are the primary cell type that constitutively express TIGIT, it has been suggested that 
the observed effects on DCs are mediated by TIGIT+ Tregs. Furthermore, Tregs expressing 
TIGIT have been shown to directly suppress Th1 and Th17 responses through the production 
of the effector molecule fibrinogen-like protein 2 (Fgl2).87
Cytotoxic Activity:
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Historically, cytotoxic activity has been associated with natural killer (NK) cells and cytotoxic 
T lymphocytes (CD8+ T cells). In 2004, Grossman et al first described granzyme-B expressing 
CD4+ Tregs capable of killing target cells in a perforin-dependent, but TCR-independent 
manner.88 Boissonnas et al subsequently showed that in a mouse tumour model, Foxp3+ T 
cells can kill antigen-specific DCs. Treg cytotoxicity has also been observed against CD4+ T 
cells in both in vitro and in vivo models. Activated Tregs upregulate tumour necrosis factor-
related apoptosis inducing ligand (TRAIL) which enhances suppressive activity as well as 
cytotoxicity against CD4+ T cells. This is entirely dependent on the TRAIL/death receptor 5 
(DR5) pathway.89 Galectin-1, a β-galactoside-binding protein known to induce T cell 
apoptosis has also been implicated in Treg cytotoxic function. Galectin-1 was found to be 
overexpressed in Tregs and galectin-1 knockout models were shown to possess reduced 
regulatory activity.90
Tissue Repair:
Aside from limiting mucosal damage through the suppression of pro-inflammatory cells 
following environmental insults like infection, Tregs may also promote tissue repair. 
Recently, the epidermal growth factor (EGF)-like molecule amphiregulin (AREG) has gained 
attention as an important regulator of tissue repair and regeneration. In a murine model of 
influenza, selective Treg deficiency in AREG leads to severe acute lung damage without any 
alterations in Treg suppressor function.  This suggests that Tregs play a direct role in tissue 
repair and maintenance that is distinct from their suppressive function.91 Treg production of 
AREG is dependent on IL-18 or IL-33 which function as endogenous danger signals or 
alarmins, in response to tissue damage.91 Studies in humans have revealed high levels of IL-
33 in inflamed lesions of IBD patients, and Tregs expressing the IL-33 receptor, ST2, are 
enriched in the colon.92–94 IL-33-Treg signalling may therefore represent an important 
pathway in both disease pathogenesis and recovery. 
TREGS AS A THERAPEUTIC PRODUCT:
In light of the vast array of preclinical data showcasing how a multitude of defects in Treg 
function contribute to autoimmunity and inflammation, including IBD, there has been great 
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interest in harnessing the suppressive ability of Tregs as a therapeutic product. 
Consequently, there are over 50 registered trials of Treg therapy that are either completed 
or ongoing (clinicaltrials.gov). Most of these trials involve adoptive cell transfer, although 
the dose of Tregs given is highly variable. In the setting of autoimmune disease and 
transplantation, the goals of treatment are the restoration of peripheral self tolerance, the 
suppression of inflammation and promotion of tissue repair.95 
In order to become a successful therapeutic product, Tregs must home to sites of 
inflammation and secondary lymphoid tissues, and must undergo TCR engagement. It has 
been demonstrated in solid organ transplantation that alloantigen-specific Tregs provide 
higher therapeutic benefits than polyclonal Tregs, without delivering a systemic 
immunosuppressive effect.96 Directing Tregs against a specific alloantigen also permits 
immunomodulatory functions to be concentrated at the site of the alloantigen source, 
circumventing the relative paucity of Tregs. An early study demonstrated that peripheral 
Treg expansion in mice could be driven by prolonged low dose subcutaneous infusion of a 
specific peptide.97 The induced Tregs had suppressive abilities, and demonstrated high 
levels of Foxp3 expression indicating a stable Treg phenotype. However, in IBD, a specific 
antigen has yet to be identified.
The relative paucity of Tregs in peripheral blood represents an obstacle to the development 
of a cellular therapy, though the optimum number of Tregs to be infused remains unclear. It 
has been suggested that the number of Tregs given should be at least as great as the 
number of Teffs in the body,98 though Tregs also exhibit the ability to confer suppressive 
ability on conventional T cells through ‘infectious tolerance’.96 In this process, the direct 
secretion of TGF-β, IL-10 and IL-35 by Tregs, and indirect induction via DCs, can generate a 
regulatory microenvironment which may partially circumvent the problem of low absolute 
numbers of Tregs.99
Several groups have developed protocols in line with GMP requirements to permit ex vivo 
cell expansion of Tregs.98,100,101 GMP-manufactured Tregs delivered in some early trials were 
only around 50% pure, but the development of plastic beads coated with stimulatory 
antibodies and the discovery of additional surface markers for Treg phenotyping mean that 
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a product with purity greater than 90% is now achievable.98 Contamination of the expansion 
product with Teffs hampers expansion,102 but the inclusion of rapamycin in cell culture 
blocks expansion of Teffs without affecting Treg proliferation, leading to the preferential 
promotion of Treg proliferation.98,103
Tregs are first isolated from peripheral blood by surface marker expression 
(CD4+CD25hiCD127lo). This can be performed using stream in air fluorescence-activated cell 
sorters (FACS) which yield a highly pure starting population, but the necessary air exposure 
requires high efficiency particulate air (HEPA) enclosures, and single use sample lines to be 
compatible with manufacturing GMP cell products. Closed system magnetic bead-activated 
cell sorting (MACS) can be adapted for large-scale isolation of human Tregs, but unlike FACS 
cannot easily distinguish surface marker expression density. A recently developed 
microfluidic chip fluorescence-activated cell sorter, the MACSQuant Tyto (Miltenyi Biotech, 
Germany) surmounts the problems of stream in air sorters, as the cells remain in a closed 
system throughout the sorting process. Expansion of the sorted cells is achieved through 
polyclonal TCR activation with anti-CD3/anti-CD28 beads.104 Tregs are sampled and checked 
for sterility and phenotype throughout the expansion process. With optimised conditions, a 
500-fold expansion can be anticipated over a 14 day period.101.
Uncertainty about the plasticity of Tregs in culture and following infusion means there is a 
theoretical concern about the development of a pro-inflammatory phenotype, which could 
lead to transplant rejection or aggravation of inflammation. However, rapamycin-expanded 
Tregs are not contaminated by IL-17-producing Th17 cells, and these cells maintain a stable 
phenotype on transfer in vivo to mice.105 Canavan et al. found that the starting population 
for Treg expansion from the peripheral blood of CD patients has a critical effect on the 
phenotype of the expanded cell population.100 Tregs from a highly pure FACS-sorted ‘naïve’ 
CD4+CD25hiCD127loCD45RA+ precursor population demonstrated enhanced suppressive 
ability and reduced Th17 plasticity in vitro compared to a FACS-sorted 
CD4+CD25hiCD127loCD45RA- or MACS-enriched CD8-CD25+ population. Rapamycin appears to 
imprint a fixed CD4+CD25hi phenotype to cells expanded from a ‘naïve’ CD45RA+ population, 
as evidenced by the retention of demethylation at the Foxp3 locus.
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TREG THERAPY IN OTHER CONDITIONS:
There is an increasing body of evidence for the use of Tregs as cellular therapy in 
autoimmune disease and transplantation (see Table 1). Adoptive transfer of Tregs to 
prevent GvHD was the first illustration of the potent therapeutic potential of Tregs in 
experimental transplantation. 
Study Clinical 
context
Enrichment 
protocol
Expansion 
protocol
Dose Study outcome
Trzonkowski et 
al. (2009)
Treatment of 
acute and 
chronic GvHD
N=2
Tregs from allogenic 
buffy coat. CD4+ 
negative bead 
selection followed by 
FACS-based sorting of 
CD4+CD25hiCD127lo 
cells
RPMI 1640 with 10% 
autologous plasma
IL-2 (1000IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
3 weeks
Acute 
GvHD: 
1x106/kg
Chronic 
GvHD: 
3x106/kg
Transient improvement 
in acute GvHD; 
alleviation of 
symptoms and 
reduction of 
immunosuppression in 
chronic GvHD
Brunstein et al. 
(2011)
Prevention of 
GvHD following 
umbilical cord 
blood 
transplantation
N=23
CD25+ bead positive 
selection
X-Vivo 15 with 10% 
human AB serum
IL-2 (300IU/ml)
Anti-CD3/anti-CD28 
beads (1:2)
18±1 days
0.1-
30x105/kg
Well –tolerated; 
reduced incidence of 
grade II-IV GvHD in 
Treg recipients
Marek-
Trzonkowska 
et al. (2012)
Safety of 
autologous in 
vitro expanded 
Tregs in 
paediatric type 1 
diabetes
N=10
FACS-based sorting of 
CD3+CD4+CD25hiCD127
lo cells
CellGro medium 
with 10% 
autologous plasma
IL-2 (1000IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
Up to 2 weeks
10-
20x106/kg
Well-tolerated; 
decreased insulin 
requirements and C-
peptide levels in Treg 
recipients
Desreumaux et 
al. (2012)
Safety and 
efficacy in 
Crohn’s disease
N=20
Culture of PBMCs with 
ovalbumin, IL-2 and IL-
4 followed by cloning 
of ovalbumin-specific 
T cells
X-Vivo 15
IL-2 (200IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
Ova-Tregs selected 
based on 
ovalbumin-specific 
IL-10 production
12 to 15 weeks
1x106-
1x109
Well-tolerated; dose-
related efficacy 
Bluestone et 
al. (2015)
Safety in adults 
with type 1 
diabetes
(N=14)
FACS-based sorting of 
CD4+CD25hiCD127lo 
cells
X-Vivo 15 with 10% 
human AB serum 
and deuterated 
glucose
IL-2 (300IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
14 days
0.05x108-
26x108
Well-tolerated, no 
significant adverse 
events. Stable C-
peptide levels and 
insulin use in recipients 
for up to two years 
post infusion
Mathew et al. 
(2018)
Safety in living 
donor kidney 
transplant 
N=9
CliniMACS plus GMP 
enrichment system 
(Miltenyi)
IL-2 (1000IU/ml)
MACS © GMP 
expansion beads 
1:1-4:1
3 weeks
0.5-5x109 Well-tolerated, no 
infections or rejection 
up to two years post 
transplant
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Table 1: Summary of clinicaltrials.gov listings for reported trials using in vitro expanded 
regulatory T cell (Treg) therapy
Graft vs. host disease (GvHD):
The risk of developing GvHD following haematopoetic stem cell transplantation (HSCT) is 
associated with low numbers of Tregs in the periphery,106 and in vivo expansion of Tregs 
post-HSCT using low dose IL-2 has demonstrated efficacy against GvHD.107,108 Studies in mice 
involving infusion of cultured CD4+CD25+ T cells resulted in a significantly reduced GvHD 
phenotype,109 and in humans it was found that infusion of freshly isolated donor Tregs given 
at the same time as haplotype mismatched HSCT prevented the development of GvHD.110 
Five trials of ex vivo expanded Tregs have to date involved small numbers of patients only, 
but suggest therapy can prevent or delay the onset of chronic GvHD111,112. Treg therapy 
seems to be effective only in the chronic form of GvHD, but this may be because of the time 
requirements to expand the cellular product which makes it difficult to administer in a 
timely manner in acute GvHD.113
Solid organ transplant:
Adoptive Treg therapy has been trialled following renal and liver transplantation, with the 
aim of inducing tolerance to the allograft and reducing the burden of long-term 
immunosuppression.114 Tregs have been shown to control immune responsiveness to 
alloantigens and contribute to ‘operational tolerance’ in preclinical transplantation 
models.115,116 Recipient-derived Tregs expanded for direct and indirect pathway 
allospecificity in vitro were able to mediate effective protection against acute and chronic 
rejection in skin and heart allografts in mice,117 and could be used to induce tolerance of a 
murine skin transplant following thymectomy and T cell depletion.118 In these models, 
alloantigen reactive Tregs were more effective at preventing graft rejection than 
polyclonally expanded Tregs104.
A phase I study in renal transplantation recruited nine living donor transplant recipients, and 
used the product of leukapharesis as the basis for ex vivo expansion of polyclonal 
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autologous Tregs.114 Alemtuzumab was given at induction to achieve lymphodepletion, on 
the basis of previous experiments suggesting a reduction in circulating Teffs worked 
synergistically with Treg infusion to prolong allograft survival.116 Recipients were switched 
from traditional immunosuppression with tacrolimus, which blocks IL-2 production, to 
sirolimus (rapamycin), which has Treg promoting activity.119 
An enhanced suppressive ability of the expanded Tregs was demonstrated when compared 
to Tregs taken directly ex vivo.114 There were no adverse infusion-related side effects, 
infections or rejection up to two years post-transplant, and there was a 5-20 fold increase in 
the number of circulating Tregs seen up to one year post-transplant. Transplant biopsies 
taken at three months did not show rejection and recipients had not developed peripheral 
donor-specific antibodies. An additional important outcome from trials in transplantation is 
that they have demonstrated that it is possible to expand Tregs from immunocompromised 
patients.120
A trial of Treg immunotherapy in liver transplantation is currently underway.121 This is 
predicated on the observation that when liver allografts in mice were infiltrated with Tregs, 
loss of Treg numbers was associated with a loss of tolerance.122 Increased frequencies of 
Tregs are also seen in human subjects who acquire ‘operational tolerance’ to their liver 
transplant.123  
Type 1 diabetes mellitus:
The development of T1DM is associated with deficits in the number and suppressive activity 
of Tregs.124  Accelerated diabetes onset is seen in both scurfy mice29 and children with 
IPEX,125 highlighting the role of Tregs in protecting pancreatic islet cells from destruction. 
Tregs have been implicated in the pathogenesis of diabetes in the non-obese diabetic (NOD) 
mouse model,126,127 and anti-CD3 antibodies have been efficacious in the treatment of 
diabetes in both mouse128,129 and human trials.130,131 Subjects exhibited lower insulin 
requirements and higher C-peptide levels at least 18 months after a short course of 
intravenous treatment, with evidence of anti-CD3 treatment inducing expansion of a 
CD4+CD25+ T cell population.129A trial of ten children treated with expanded polyclonal Tregs 
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within two months of their diagnosis demonstrated statistically lower insulin requirements 
and C peptide levels compared with matched controls up to six months post infusion, with 
two patients remaining insulin-independent.124 There were no serious adverse events up to 
one year following infusion. 
In a phase I open-label trial of 14 adult patients infused with ex vivo expanded Tregs in 
escalating doses, 7 of 14 patients had stable C peptide levels and insulin use for up to two 
years following infusion.101 However, the study was not powered to detect significant 
clinical improvement. There were no infusion reactions or therapy-related serious adverse 
events. Phenotypic analysis of the cell product after expansion and after infusion identified 
stable surface marker expression, demonstrating that the infused Tregs did not acquire a 
pathological phenotype. High throughput TCR-β sequencing analysis indicated that 
expanded Tregs retained a high degree of diversity.
Adoptively transferred Tregs were tagged by labelling the deoxyribose moiety of replicating 
DNA during expansion ex vivo, through addition of deuterated [6,6-2H2] glucose to Treg 
culture throughout the 14 day expansion period.101 Patient samples were analysed by gas 
chromatography mass spectrometry (GC-MS) for deuterium enrichment to create 
pharmacokinetic curves. Adoptively transferred T cell numbers peaked at two weeks 
following infusion, but were still detectable at up to 25% of the peak level at one year in 
peripheral blood. Significantly, deuterium labelling was never found in non-Tregs, indicating 
the stability of infused Tregs. However, due to the nature of this study, the stability of these 
cells was not assessed within the target tissue.
TREG THERAPY IN INFLAMMATORY BOWEL DISEASE:
A local imbalance between Treg and Teff responses plays a key role in the development of 
gut inflammation in IBD.8 T cell gut homing is mediated by specific interaction between 
integrin α4β7 and its ligand MAdCAM-1.132,133 Several groups have shown that transfer of 
Tregs into mice leads to clinical and histological improvement in colitis,14,134,135 and 
rapamycin-expanded Tregs ameliorated established colitis in a SCID mouse model.136 
Polyclonality of the TCR is likely to be an important requirement for Tregs to maintain 
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intestinal homeostasis in vivo. Mice which express a restricted TCR repertoire develop 
spontaneous colitis due to a loss of tolerance to intestinal microbiota.137
Several groups have demonstrated that it is feasible to extract Tregs from patients, and 
expand them in vitro under GMP conditions, including from subjects receiving thiopurines 
and anti-TNFα medications.98,100,103,138 Even after prolonged culture, these Tregs maintained 
Foxp3 expression and demonstrated enhanced suppression of autologous T cells. 
Uncertainty regarding the potential for adoptively transferred Tregs to express IL-17 and 
exacerbate CD lesions is a concern. However, the administration of pro-inflammatory 
cytokines (IL-1, IL-2, IL-6, IL-21, IL-21 and TGF-β) failed to induce IL-17 production by 
CD45RA+ expanded Tregs in vitro.100
Antigen specific vs. polyclonal Treg cell products for Crohn’s disease:
No antigens have yet been verified as causal in CD. Attempts have been made to identify 
shared TCRs between CD sufferers with the aim of discovering target antigens.139–141 This 
work has observed that the CD4 TCR repertoires are significantly more diverse in patients 
with CD and UC than healthy controls.142 This may be explained by GI barrier disruption 
increasing the number of antigen presentation events in comparison to a healthy gut. 
Resolving a target from the GI peptidome is challenging due to the heterogenous nature of 
the environment. Developments in the understanding of non-conventional epitopes are also 
increasing the magnitude and complexity of the peptidome itself.143 In the absence of a 
known target, the broad reactivity of a polyclonal Treg product may be advantageous, as the 
cell product will recognise millions of putative epitopes, increasing the likelihood of TCR 
engagement and subsequent Treg activation.  Sequencing of isolated Tregs from GI biopsies 
post transfer may yield novel targets, upon which chimeric antigen receptor technology 
could be readily implemented.144 
For Treg therapy to be effective in IBD, expanded Tregs must have the ability to home to the 
gut.145 A French group reported the results of an open label multicentre phase I/IIa trial of 
ovalbumin-specific Tregs in 20 patients with refractory CD.146 Ovalbumin is a common food 
antigen, and is not implicated in intestinal inflammation in animal models or in patients with 
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CD. Its distribution along the digestive tract can be used to activate Tregs locally. In the 
study, this was facilitated through ingestion of meringue cakes by subjects.146
The cell product was cultured in the presence of ovalbumin, and trial subjects received a 
dose of 106-109 Tregs.146 Patients enrolled in the study had at least moderately active CD, 
with a Crohn’s Disease Activity Index (CDAI) greater than or equal to 220 within six months 
of screening, and a washout period was required for immunosuppression and anti-TNFα 
therapy. The infusion was well tolerated, with mild GI symptoms and CD flares being the 
most commonly reported adverse effects. Two patients experienced thrombotic events, but 
these are known to occur more frequently in inflammatory conditions including active CD.147 
Eight (40%) patients had a significant CDAI response at weeks five and eight after treatment, 
with two patients experiencing sustained remission. Overall, the results suggested good 
tolerability in this disease group with possible signals of efficacy.
In the absence of a known antigen, other methods must be used to direct the Tregs to the 
areas of inflammation. A recent study has shown that a highly specific retinoic acid receptor 
α (RARα) agonist induces expression of Integrin α4β7 (the ligand of MAdCAM-1) on the Treg 
surface. Adoptive transfer of RARα agonist-treated Tregs leads to improved Treg trafficking 
to gut tissue in a humanised mouse model of colitis.100 Supporting this mechanism for 
resolving inflammation, another group have demonstrated that DCs can be engineered de 
novo to produce high concentrations of RA.148 When transferred to mice, the RA-secreting 
DCs were able to augment the expression of Foxp3 and the gut-homing receptor CCR9 in 
native Tregs with the subsequent suppression of colitis. 
The RARα agonist treated cell product forms the basis of the TRIBUTE trial (ClinicalTrials.gov 
Identifier: NCT03185000), a double-blinded placebo-controlled phase I/IIa trial of adoptive 
Treg therapy in CD.
FUTURE DEVELOPMENTS IN TREG THERAPY:
The potential therapeutic benefits of adoptive cell therapy are being explored in numerous 
autoimmune conditions. In SLE, adoptive transfer of ex vivo expanded Tregs in mice delayed 
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the onset of renal complications and prolonged survival,149,150 and a pilot study of low dose 
IL-2 in 37 patients led to increased circulating peripheral Treg numbers and decreased SLE 
disease activity scores.151 Adoptive Treg transfer in a single patient with cutaneous lupus did 
not lead to clinical benefit, but increased percentages of highly activated Tregs were 
identified in biopsies taken from diseased skin.152 Treg accumulation in skin was associated 
with a marked attenuation of IFN-, which was more pronounced relative to peripheral 
blood. 
Preliminary results from mouse models suggest a role for Treg therapy in conditions as 
diverse as pemphigus vulgaris,153 autoimmune hepatitis,154 multiple sclerosis,113 asthma, 
and allergy, in which antigen-specific Tregs may represent a viable therapeutic option.155,156
Many ongoing challenges exist for the advancement of Treg therapy. Uncertainties remain 
about the optimal timing of ex vivo Treg expansion, and whether IL-2 administration would 
be a useful adjunct to support a Treg population in vivo.101,107 In addition, concomitant 
treatment of autoimmune disease with immunosuppressive drugs may affect the function 
of adoptively transferred cells.95 
The optimal dosing strategy for Treg therapy also r mains unclear, although data tracking 
the survival of deuterium-labelled Tregs in vivo could be invaluable in informing a suitable 
dosing regimen.101 A two-phase decay in numbers of deuterium-labelled Tregs has been 
seen, with 75% of the peak level lost at three months. However, levels stabilised at one 
year, with up to 25% of peak Treg numbers remaining in the peripheral circulation.  The 
decrease in labelled Tregs may represent cell death, trafficking to lymphoid tissue and sites 
of inflammation, or proliferation of the Treg compartment leading to dilution of deuterium 
enrichment. Reassuringly, at no point during the trial was deuterium detected in cell 
populations other than Tregs, suggesting a stable phenotype in vivo.101 
Tracking of TCR clonotypes may also provide useful data on Treg kinetics and dispersal. 
Analysis of the TCR repertoire has suggested that the kinetics of transferred Tregs in 
peripheral blood varies significantly between individuals157. In a descriptive study, the TCR 
Vα chain was sequenced in two patients receiving donor Treg infusion157. Treg therapy 
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altered the patients’ peripheral TCR repertoire considerably towards that of the infused cell 
product, but to different degrees in each patient. Importantly, the degree of alteration of 
the TCR repertoire appeared to correlate with clinical response. This suggests that 
monitoring TCR repertoires following adoptive cell transfer may provide clinically 
meaningful information.
CONCLUSION:
There is now robust evidence of the therapeutic potential of Treg therapy in Crohn’s 
disease. Trials in multiple autoimmune diseases and results from use of ovalbumin-specific 
Tregs in IBD show promising early signs of efficacy. The safety signal is reassuring, with 
evidence that the adoptively transferred Treg phenotype is stable in vivo. Results from 
deuterium labelling suggest that infused Tregs may be able to exert a long-lasting systemic 
effect with labelled cells detectable up to a year after infusion. It is hoped that upcoming 
early phase clinical trials in patients with Crohn’s disease will inform safety, dosing, and Treg 
kinetics and dispersal allowing further development of a novel therapeutic option in this 
hard-to-treat population. 
FIGURE LEGEND:
Figure 1. Mechanisms of Treg mediated suppression
Tregs utilize a multitude of mechanisms to promote a tolerogenic microenvironment and 
tissue repair. (A) Secretion of the anti-inflammatory cytokines, IL-10, TGF-β and IL-35, not 
only inhibit Teff proliferation, but also suppress Th1 and Th17 effector function, both of 
which are key mediators of IBD. (B) Tregs express the high affinity IL-2 receptor -chain 
(CD25) consuming local IL-2 with greater affinity than effector cells. Teffs which are ‘starved’ 
of IL-2 exhibit restricted proliferation and undergo apoptosis. (C) Tregs co-expressing CD39 
and CD73 disrupt metabolic processes in effector cells by converting ATP into peri-cellular 
adenosine, a potent inhibitor of Teff function. Additionally, adenosine stimulates TGF- 
production, promoting development of pTregs. (D) Tregs are capable of secreting perforin, 
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granzyme B and galectin-1 which are directly cytotoxic against Teffs. Activated Tregs also 
express TRAIL, inducing apoptosis of Teffs through the TRAIL/DR5 pathway. (E) Expression of 
CTLA-4 degrades DC-derived CD80 and CD86 leading to impaired CD28-mediated co-
stimulation of T cells. DC function is further inhibited through the interaction of Treg-
derived TIGIT and CD155 on DCs. This induces IL-10 production and suppresses IL-12. (F) In 
response to alarmins, Tregs produce AREG, an important regulator of tissue repair and 
regeneration. AREG, amphiregulin; ATP, adenosine tri-phosphate; CTLA-4, cytotoxic T 
lymphocyte associated protein 4; DC, dendritic cell; DR5, death receptor 5; IBD, 
inflammatory bowel disease; pTregs, peripheral regulatory T cells; Teff, T effector 
lymphocyte; TGF-, transforming growth factor beta; Th1, T helper 1 cell; Th17, T helper 17 
cell; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TRAIL, TNF-related apoptosis-
inducing ligand; Treg, regulatory T cell. Figure generated using BioRender© illustration 
software.
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Figure	1.	Mechanisms	of	Treg	mediated	suppression	
Tregs	 utilize	 a	multitude	 of	mechanisms	 to	 promote	 a	 tolerogenic	microenvironment	 and	
tissue	 repair.	 (A)	 Secretion	of	 the	 anti-inflammatory	 cytokines,	 IL-10,	 TGF-β	 and	 IL-35,	 not	
only	 inhibit	 Teff	 proliferation,	 but	 also	 suppress	 Th1	 and	 Th17	 effector	 function,	 both	 of	
which	 are	 key	mediators	 of	 IBD.	 (B)	 Tregs	 express	 the	 high	 affinity	 IL-2	 receptor	α-chain	
(CD25)	consuming	local	IL-2	with	greater	affinity	than	effector	cells.	Teffs	which	are	‘starved’	
of	 IL-2	exhibit	restricted	proliferation	and	undergo	apoptosis.	 (C)	Tregs	co-expressing	CD39	
and	CD73	disrupt	metabolic	processes	 in	effector	 cells	by	converting	ATP	 into	peri-cellular	
adenosine,	 a	 potent	 inhibitor	 of	 Teff	 function.	 Additionally,	 adenosine	 stimulates	 TGF-β	
production,	promoting	development	of	pTregs.	 (D)	Tregs	are	capable	of	secreting	perforin,	
granzyme	 B	 and	 galectin-1	which	 are	 directly	 cytotoxic	 against	 Teffs.	 Activated	 Tregs	 also	
express	TRAIL,	inducing	apoptosis	of	Teffs	through	the	TRAIL/DR5	pathway.	(E)	Expression	of	
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CTLA-4	 degrades	 DC-derived	 CD80	 and	 CD86	 leading	 to	 impaired	 CD28-mediated	 co-
stimulation	of	T	cells.	DC	function	is	further	inhibited	through	the	interaction	of	Treg-derived	
TIGIT	and	CD155	on	DCs.	This	induces	IL-10	production	and	suppresses	IL-12.	(F)	In	response	
to	alarmins,	Tregs	produce	AREG,	an	important	regulator	of	tissue	repair	and	regeneration.	
AREG,	 amphiregulin;	 ATP,	 adenosine	 tri-phosphate;	 CTLA-4,	 cytotoxic	 T	 lymphocyte	
associated	 protein	 4;	 DC,	 dendritic	 cell;	 DR5,	 death	 receptor	 5;	 IBD,	 inflammatory	 bowel	
disease;	 pTregs,	 peripheral	 regulatory	 T	 cells;	 Teff,	 T	 effector	 lymphocyte;	 TGF-β,	
transforming	 growth	 factor	 beta;	 Th1,	 T	 helper	 1	 cell;	 Th17,	 T	 helper	 17	 cell;	 TIGIT,	 T-
cell	immunoreceptor	 with	 Ig	 and	 ITIM	 domains;	 TRAIL,	 TNF-related	 apoptosis-inducing	
ligand;	Treg,	regulatory	T	cell.	Figure	generated	using	BioRender©	illustration	software.	
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76 ABSTRACT:
77
78 The prevalence of inflammatory bowel disease is rising in the Western world. Despite an 
79 increasing repertoire of therapeutic targets, a significant proportion of patients suffer 
80 chronic morbidity. Studies in mice and humans have highlighted the critical role of 
81 regulatory T cells in immune homeostasis, with defects in number and suppressive function 
82 of regulatory T cells seen in Crohn’s disease patients. We review the function of regulatory T 
83 cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We 
84 explore the principles and challenges of manufacturing a cell therapy, and discuss clinical 
85 trial evidence to date for their safety and efficacy in human disease, with particular focus on 
86 the development of a regulatory T cell therapy for Crohn’s disease. 
87
88 Keywords: Crohn’s disease, Immunology, Immunoregulation, Intestinal T cell, T lymphocytes
89
90 INTRODUCTION:
91
92 Inflammatory bowel disease (IBD), chiefly comprising Crohn’s disease (CD) and ulcerative 
93 colitis (UC), is a chronic inflammatory group of disorders of the gastrointestinal (GI) tract 
94 arising from overexuberant innate and adaptive immune responses to environmental 
95 factors in genetically susceptible individuals. IBD affects at least 0.5% of the population in 
96 the Western world with 1 million sufferers in USA and 2.5 million in Europe.1 Global 
Page 38 of 68
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4
97 prevalence continues to increase, largely driven by rising numbers of patients in newly 
98 industrialised regions including India and Asia.1 The burden of disease is significant with 20-
99 25% of patients experiencing chronic continuous symptoms which contributes to higher 
100 rates of unemployment, sick leave and permanent work disability.2 Even with an aggressive 
101 top-down approach to therapy, the majority of patients fail to achieve prolonged, steroid-
102 free remission and are at particular risk of requiring surgical intervention. Cumulative 
103 surgery rates in CD are high in Europe with 30-50% of patients requiring surgical 
104 intervention and up to 20% needing a reoperation 5-10 years from diagnosis.2
105
106 As our understanding of the pathophysiology of IBD and its socioeconomic impact has 
107 evolved, there has been great impetus to identify novel therapeutic targets to add to the 
108 existing arsenal of immunomodulators and biologics. These have focussed on a variety of 
109 areas including targeting lymphocyte trafficking (vedolizumab, ozanimod, anti-MAdCAM1) 
110 and activation (anti-IL6, anti-IL12/IL23), modulating intestinal barrier function 
111 (phosphatidylcholine), matrix remodelling (STNM-01, MMP9 blocker) and manipulation of 
112 gut microbiota (faecal microbiota transplant).3 An important pathological process 
113 increasingly recognised as driving intestinal inflammation and autoimmunity is the loss of 
114 immune homeostasis secondary to qualitative or quantitative defects in the regulatory T cell 
115 (Treg) pool.
116
117 Tregs are CD4+ T cells that characteristically express the high affinity IL-2 receptor -chain 
118 (CD25), and master transcription factor Forkhead box P-3 (Foxp3), which is essential for 
119 their suppressive phenotype and stability.4–6 As activated CD4+ T cells can upregulate CD25 
120 expression, an additional defining feature of Tregs is the absence of IL-7 receptor -chain 
121 (CD127).7 Their primary function is as dominant controllers of self-tolerance, tissue 
122 inflammation and long-term immune homeostasis. Despite making up only 5-10% of the 
123 peripheral CD4+ T cell pool, Tregs exert powerful inhibitory effects on effector cells through 
124 a variety of mechanisms including cytokine secretion, metabolic disruption, inhibition of 
125 dendritic cells (DCs) and cytolysis. These mechanisms have been rigorously examined using 
126 animal models and shown to protect against the development of intestinal inflammation. 
127 Studies in patients with IBD have identified defects in the number and distribution of Tregs, 
128 and their ability to traffic to the GI tract.8 Additionally, resistance to Treg-mediated 
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5
129 suppression has been noted in lamina propria T effector cells (Teffs).9 These factors are 
130 likely to be pivotal in driving intestinal inflammation.
131
132 There is growing interest in the therapeutic potential of adoptively transferring healthy 
133 Tregs into patients with a wide range of conditions, including IBD and autoimmune disease, 
134 in an attempt to shift the balance in areas of active inflammation towards a more 
135 tolerogenic microenvironment. Early phase clinical trials have already reported in the fields 
136 of solid organ transplantation, graft-versus-host disease (GvHD) and type 1 diabetes mellitus 
137 (T1DM) with reassuring safety data and potential signals of efficacy. 
138
139 This review provides a summary of the suppressive mechanisms utilised by Tregs and 
140 highlights seminal work linking intestinal inflammation with loss of Treg function in both 
141 animal models of disease and in humans. Additionally, we review ongoing clinical trials with 
142 Treg therapy and outline an entirely novel therapeutic strategy for CD using Tregs expanded 
143 under GMP (Good Manufacturing Practice) conditions that will be adoptively transferred to 
144 patients in an attempt to ameliorate intestinal inflammation and restore immune 
145 homeostasis.
146
147 TREGS IN HEALTH AND DISEASE:
148
149 Tregs can be broadly divided into two groups, thymic Tregs (tTregs) or peripherally induced 
150 Tregs (pTregs) based on their developmental origin. Tregs generated in the thymus (tTregs) 
151 in the early neonatal period migrate to peripheral organs where they maintain tolerance. 
152 This was discovered in 1969 by Nishizuka and Sakakura who showed that in mice, 
153 thymectomy 3 days after birth led to the depletion of Foxp3+ Tregs and development of 
154 autoimmune oophoritis.10 In contrast, mice who had thymectomy at day 7 remained healthy 
155 as the tTregs had already migrated to the periphery by this point.11 Over a decade later, 
156 Sakaguchi et al demonstrated that day-3 thymectomy autoimmune oophoritis could be 
157 prevented with CD4+ T cell inoculation from healthy syngeneic donors. Conversely, the 
158 adoptive transfer of T cells from these sick mice were capable of inducing autoimmune 
159 disease in healthy T cell deficient mice.12 Similar findings were noted in rats that underwent 
160 adult thymectomy and irradiation resulting in lymphopenia, autoimmune diabetes and 
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161 insulitis. An injection of CD45RC(low) T cells from healthy donors were capable of 
162 preventing disease.13 Mottet et al subsequently described CD25-expressing CD4+ T cells that 
163 were able to cure established T cell transfer colitis.14 By the early 2000’s it was clear that a 
164 thymically-derived CD4+CD25+ T cell population possessed the ability to suppress 
165 autoreactive T cells and eliminate autoimmunity.  
166
167 Peripherally induced Tregs (pTregs) were first described in 2003 where naïve CD4+CD25- T 
168 cells could be converted into Foxp3-expressing CD4+CD25+ Tregs by T cell receptor (TCR) co-
169 stimulation in the presence of TGF-β.15 pTreg conversion in gut-associated lymphoid tissues 
170 (GALT) was enhanced when naïve CD4+ T cells encountered antigen in the presence of TGF-
171 β, IL-2 and retinoic acid (RA).16,17 This is facilitated by CD103+ DCs conditioned by the 
172 intestinal microenvironment to produce or activate TGF-β and provide RA.18,19 In the 
173 absence of CD103 expression, DCs fail to induce Treg development and produce 
174 proinflammatory cytokines.18,20 Additionally, in patients with UC, CD103+ DCs appear to 
175 have impaired ability to generate pTregs, but induce colitogenic T helper (Th) 1, Th2 and 
176 Th17 responses suggesting CD103+ DC-mediated pTreg induction is functionally relevant in 
177 IBD pathogenesis.21 
178
179 Distinguishing tTregs from pTregs can be difficult as no definitive markers exist. Recently, 
180 the expression of the membrane protein neuropilin-1 (Nrp1) and the transcription factor 
181 Helios by tTregs but not by pTregs has been used to differentiate Treg subsets.22 The 
182 significance of this lies in the epigenetic differences in the Foxp3 locus rendering pTregs less 
183 stable and more likely to demonstrate plasticity towards a Th17 cell phenotype under 
184 inflammatory conditions.23 The developmental origin of Tregs selected for expansion as a 
185 cell therapy product is therefore an important consideration and will be addressed in more 
186 detail later in this review.
187
188 The first study identifying Tregs in humans was published in 2001. Baecher-Allan et al 
189 characterised CD4+CD25+ T cells in the thymus and peripheral blood which exhibited anti-
190 inflammatory and suppressive properties.24 Subsequent work established Foxp3 as the 
191 master transcription factor for Tregs.4,6,25 Foxp3 can however be expressed transiently in 
192 non-regulatory CD4+ T cells upon TCR activation and the CD4+CD25+CD127lo surface 
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7
193 phenotype must be used to define Tregs.26 Inactivating mutations in Foxp3 clinically 
194 manifest as severe autoimmunity with a scurfy phenotype in mice and IPEX syndrome 
195 (‘immune dysregulation, polyendocrinopathy, enteropathy, X-linked’) in humans.27–30 With 
196 autoimmune enteropathy (manifesting as chronic diarrhoea and malabsorption) a 
197 predominant feature, attention was focussed on the functional role of Tregs within the GI 
198 tract. 
199
200 Peripheral Tregs are found in abundance in the intestinal lamina propria where interactions 
201 with environmental antigens can shape phenotypic differences and transcription factor 
202 expression.31 The gut microbiota represents a substantial antigen load driving the expansion 
203 of colonic pTregs that co-express the Th17 master transcription factor RORt.32 These 
204 Foxp3+ RORt+ pTregs have a stable regulatory phenotype and provide tolerance against the 
205 gut microbiota.33,34 Conversely, RORt- pTregs are found in the small intestine where they 
206 are induced by dietary antigens and repress underlying Th1 cell responses to ingested 
207 proteins.35 Finally, an intestinal tTreg population that co-express the Th2 master 
208 transcription factor, GATA3, has been shown to mediate repair of the intestinal mucosa. 
209 GATA3+ tTregs express high levels of the IL-33 receptor, ST2, and amphiregulin, an 
210 epidermal growth factor receptor ligand involved in tissue repair.36,37 
211
212 Following on from the fundamental observations linking Treg dysfunction to an array of 
213 autoimmune polyendocrine syndromes, studies began to emerge identifying defects in 
214 either number or function of peripheral blood Tregs in autoimmune disorders including IBD, 
215 type 1 diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis 
216 and rheumatoid arthritis.8,38–42 Maul et al observed that in patients with active IBD, the 
217 intestinal lamina propria Treg pool was significantly smaller than that of a positive control, 
218 namely diverticulitis.8 Additionally, in these patients, the peripheral blood Treg pool was 
219 smaller than that of inactive IBD or diverticulitis.8 Interestingly, the peripheral blood Tregs 
220 retained their suppressive capacity suggesting that disease may be driven by ineffective 
221 trafficking to the gut and reduced numbers of Tregs. Furthermore, colitogenic T cells from 
222 IBD patients appear to be resistant to TGF-β1-mediated Treg suppression highlighting an 
223 additional defect in immunological tolerance that may drive disease.43
224
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8
225 TREG FUNCTION AND COLITIS:
226
227 Tregs function as key mediators of peripheral tolerance through direct cellular contact and 
228 paracrine actions on tissues where they reside.44,45 It is essential that Tregs effectively traffic 
229 to target organs where they promote a tolerogenic microenvironment. An important 
230 example is IL-10-secreting Tregs that reside in the GI mucosa and control inflammatory 
231 responses induced by environmental insults. Selective disruption of IL-10 expression in 
232 these Tregs has been shown to cause spontaneous colitis.46 This is one of many modalities 
233 that Tregs can employ to maintain immune homeostasis at the mucosal interface. Others 
234 include inhibitory cytokine secretion, cytolysis of effector cells, metabolic disruption, 
235 neutralization of antigen presenting cells (APC) and promotion of tissue repair.47 These 
236 functions will be reviewed in further detail outlining their associations with intestinal 
237 inflammation (see Figure 1).
238
239 Inhibitory Cytokines:
240
241 The Treg cytokine repertoire includes the anti-inflammatory molecules IL-10, TGF-β and IL-
242 35. The expression of IL-10 and IL-35 requires TCR signalling, suggesting that Treg function in 
243 part relies on antigen encounter in the local microenvironment.48 Pioneering work by 
244 Powrie et al over 20 years ago showcased the potent inhibitory ability of IL-10, where 
245 recombinant IL-10 therapy ameliorated established T cell transfer colitis.49 Subsequently, 
246 the co-transfer of CD45RB(low) T cells were shown to prevent colitis and IL-10 was 
247 identified as an essential mediator for this in vivo suppression.50 The suppressive effects of 
248 Treg-derived IL-10 in mice appear to be specific for mucosal surfaces rather than controlling 
249 systemic autoimmunity.46 Further studies have demonstrated that IL-10 induces robust 
250 activation of a STAT3-dependent Th17 suppression program in Tregs, downstream of IL-
251 10R.51 This suppresses pathogenic Th17 cell responses and ablation of IL-10R in Tregs has 
252 been shown to cause colitis. It is therefore plausible that disordered IL-10 signalling may 
253 contribute to aberrant Th17 activity, which is implicated in IBD.52 In fact, there have been 
254 several cases of homozygous loss-of-function mutations in Il-10 and Il-10r arising in 
255 individuals from consanguineous marriages. These resulted in infantile severe, progressive, 
256 intractable Crohn’s-like colitis.53
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9
257
258 TGF-β plays an important role inducing pTreg formation upon antigen encounter in GALT 
259 and has a functional role in suppressing pro-inflammatory pathways.54 Tregs are capable of 
260 producing TGF-β, which profoundly suppresses the proliferation of Teffs.55 Treg-derived 
261 TGF-β1 inhibits Th1-cell differentiation and IBD in a transfer model of colitis.56 Conversely, 
262 Tregs from TGF-β1-deficient mice fail to suppress intestinal inflammation in a SCID transfer 
263 model of colitis.55 Human studies have supported these early findings; a study on healthy 
264 human colonic biopsies and lamina propria mononuclear cells (LPMC) treated with anti-TGF-
265 β neutralising antibody showed that TGF-β is a critical suppressor of T-bet-dependent Teff 
266 proliferation and Th1 cytokine expression.57 This suggests a role for TGF-β in suppressing 
267 intestinal inflammation in humans. Indeed, MacDonald et al have shown that colonic tissue 
268 and isolated T cells from patients with CD overexpress Smad7, an inhibitor of TGF-β1 
269 signalling.58 Furthermore, colonic LPMCs from CD patients were resistant to Treg-mediated 
270 suppression, a phenomenon that could be reversed with Smad7 antisense treatment.43 
271 Smad 7 antisense therapy (Mongersen) was subsequently evaluated in CD but, despite 
272 promising early phase data, a phase III clinical trial was terminated early due to lack of 
273 benefit.59,60 Although Mongersen may overcome Teff resistance to TGF-β, it is possible in CD 
274 there are insufficient numbers of functional Tregs in the mucosal environment to produce 
275 TGF-β explaining the disappointing trial outcome .
276
277 IL-35 is a heterodimer of Ebi3 and IL-12 that is constitutively expressed in Foxp3+ Tregs but 
278 not Teffs. It was first described in 2007 where Ebi3-/- and IL-12 -/- Tregs were shown to have 
279 significantly reduced regulatory activity in vitro and failed to cure T cell transfer colitis in 
280 vivo.61 Additionally, IL-35 can induce the generation of a regulatory population from naïve 
281 mouse or human CD4+ T cells. These so-called iT(R)35 cells mediate suppression via IL-35 
282 alone, do not express Foxp3, and are strongly suppressive and stable in vivo.62 In both 
283 dextran sulphate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis, 
284 recombinant IL-35 therapy can treat disease through downregulation of the Th1 and Th17 
285 master transcription factors, T-bet and RORC, respectively, and through inhibition of IFN-, 
286 IL-6 and IL-17.63 
287
288 Inhibition of Metabolic Processes:
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289
290 While Tregs are not known to produce IL-2, their development and function is critically 
291 dependent on this cytokine. IL-2 and the transcription factor STAT5, downstream of IL-2 
292 receptor (IL-2R), induce the expression of Foxp3 and differentiation of tTregs.64 
293 Furthermore, STAT5 activation driven by IL2R signalling enhances the suppressor function of 
294 differentiated Tregs.65 An absence of IL-2 signalling has been shown to reduce the number 
295 and functional activity of Tregs, predisposing to autoimmunity and inflammation.66,67 The 
296 structural conformation of IL-2R in Tregs provides a competitive advantage for IL-2-receptor 
297 engagement over alternative cell subsets. Tregs abundantly express IL-2 receptor -chain 
298 (CD25), which together with the common -chain (c, CD132) and IL-2 receptor -chain 
299 (CD122) form a characteristic three subunit receptor configuration. This confers a ~1000-
300 fold increase in receptor affinity for IL-2 over Teffs.68 In a pro-inflammatory environment 
301 dominated by actively dividing effector cells, Tregs have the ability to “consume” local IL-2, 
302 starving effector cells of this essential cytokine for survival and proliferation.45,69 Moreover, 
303 this mechanism has been shown to induce the apoptosis of effector cells.70 This highlights 
304 an important TCR-independent paracrine mode of suppression in local tissues, facilitated 
305 through the constitutive expression of high affinity IL-2R (containing CD25). There have 
306 been a handful of cases of CD25 deficiency in humans often manifesting in an IPEX-like 
307 syndrome.71–73 A notable case who presented with autoimmune enteropathy at 6 months 
308 had Foxp3+ Tregs with defective IL-10 expression suggesting that IL-2 responsiveness is 
309 important for Treg-mediated IL-10 production.74
310
311 Tregs can also interfere with adenosine triphosphate (ATP) metabolism to dampen pro-
312 inflammatory responses. Tregs co-express the ectoenzymes CD39 and CD73 responsible for 
313 the degradation of ATP and generation of pericellular adenosine.75 Adenosine stimulates the 
314 A2A receptor on Teffs exerting potent inhibitory effects. Activation of the A2A receptor also 
315 inhibits IL-6 expression while enhancing the production of TGF-.76 This promotes the 
316 development of adaptive induced Tregs and simultaneously inhibits pro-inflammatory Th17 
317 cell formation. Furthermore, signalling through the A2A receptor appears to control in vivo 
318 murine colitis.77 
319
320 Neutralisation of Dendritic Cell Function:
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321
322 The activation of T cells requires TCR-antigen/MHC engagement in the context of a 
323 secondary signal, namely T cell-derived CD28 binding the DC B7 ligands, CD80 and CD86. 
324 This process is negatively regulated through the production of cytotoxic T lymphocyte 
325 antigen 4 (CTLA-4) which is constitutively expressed in Foxp3+ Tregs.78 CTLA-4-expressing 
326 cells can capture CD80 and CD86 by a process of trans-endocytosis and degrade these 
327 ligands, resulting in impaired co-stimulation via CD28.79 This is a functionally significant 
328 process with Treg-conditioned DCs inducing poor T cell proliferation.80 An additional 
329 mechanism mediated through the interaction of CTLA-4 and CD80/CD86 is the upregulation 
330 of indoleamine 2, 3-deoxygenase in DCs. This is a potent regulatory molecule which 
331 catabolises the essential amino acid tryptophan to the pro-apoptotic metabolite kynurenine 
332 leading to suppression of Teff function.64 In vivo models have demonstrated that CTLA-4 is 
333 essential in preventing autoimmunity. Selective deletion of CTLA-4 in Tregs of BALB/c mice 
334 results in fatal T cell mediated autoimmune disease at just 20 days of age.81 Additionally, 
335 several cases of germline heterozygous mutations in CTLA-4 have been identified in 
336 humans.82 CTLA-4 haploinsufficiency resulted in dysregulation of Tregs, hyperactivation of 
337 Teffs and lymphocytic infiltration of target organs including the GI tract. It was recently 
338 discovered that LRBA (lipopolysaccharide-responsive and beige-like anchor protein) 
339 regulates CTLA-4 expression, where mutations in LRBA lead to reduced levels of CTLA-4.83 
340 These mutations are commonly associated with primary immunodeficiency, reduced Treg 
341 numbers and susceptibility to IBD.84,85  
342
343 Recently, the coinhibitory molecule TIGIT has been described as an inhibitor of autoimmune 
344 responses through its interactions with DCs and T cells. TIGIT interacts with its ligand CD155 
345 on DCs to induce IL-10 and suppress IL-12 production, thereby inhibiting Th1 responses.86 As 
346 Tregs are the primary cell type that constitutively express TIGIT, it has been suggested that 
347 the observed effects on DCs are mediated by TIGIT+ Tregs. Furthermore, Tregs expressing 
348 TIGIT have been shown to directly suppress Th1 and Th17 responses through the production 
349 of the effector molecule fibrinogen-like protein 2 (Fgl2).87
350
351 Cytotoxic Activity:
352
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353 Historically, cytotoxic activity has been associated with natural killer (NK) cells and cytotoxic 
354 T lymphocytes (CD8+ T cells). In 2004, Grossman et al first described granzyme-B expressing 
355 CD4+ Tregs capable of killing target cells in a perforin-dependent, but TCR-independent 
356 manner.88 Boissonnas et al subsequently showed that in a mouse tumour model, Foxp3+ T 
357 cells can kill antigen-specific DCs. Treg cytotoxicity has also been observed against CD4+ T 
358 cells in both in vitro and in vivo models. Activated Tregs upregulate tumour necrosis factor-
359 related apoptosis inducing ligand (TRAIL) which enhances suppressive activity as well as 
360 cytotoxicity against CD4+ T cells. This is entirely dependent on the TRAIL/death receptor 5 
361 (DR5) pathway.89 Galectin-1, a β-galactoside-binding protein known to induce T cell 
362 apoptosis has also been implicated in Treg cytotoxic function. Galectin-1 was found to be 
363 overexpressed in Tregs and galectin-1 knockout models were shown to possess reduced 
364 regulatory activity.90
365
366 Tissue Repair:
367
368 Aside from limiting mucosal damage through the suppression of pro-inflammatory cells 
369 following environmental insults like infection, Tregs may also promote tissue repair. 
370 Recently, the epidermal growth factor (EGF)-like molecule amphiregulin (AREG) has gained 
371 attention as an important regulator of tissue repair and regeneration. In a murine model of 
372 influenza, selective Treg deficiency in AREG leads to severe acute lung damage without any 
373 alterations in Treg suppressor function.  This suggests that Tregs play a direct role in tissue 
374 repair and maintenance that is distinct from their suppressive function.91 Treg production of 
375 AREG is dependent on IL-18 or IL-33 which function as endogenous danger signals or 
376 alarmins, in response to tissue damage.91 Studies in humans have revealed high levels of IL-
377 33 in inflamed lesions of IBD patients, and Tregs expressing the IL-33 receptor, ST2, are 
378 enriched in the colon.92–94 IL-33-Treg signalling may therefore represent an important 
379 pathway in both disease pathogenesis and recovery. 
380
381 TREGS AS A THERAPEUTIC PRODUCT:
382
383 In light of the vast array of preclinical data showcasing how a multitude of defects in Treg 
384 function contribute to autoimmunity and inflammation, including IBD, there has been great 
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385 interest in harnessing the suppressive ability of Tregs as a therapeutic product. 
386 Consequently, there are over 50 registered trials of Treg therapy that are either completed 
387 or ongoing (clinicaltrials.gov). Most of these trials involve adoptive cell transfer, although 
388 the dose of Tregs given is highly variable. In the setting of autoimmune disease and 
389 transplantation, the goals of treatment are the restoration of peripheral self tolerance, the 
390 suppression of inflammation and promotion of tissue repair.95 
391
392 In order to become a successful therapeutic product, Tregs must home to sites of 
393 inflammation and secondary lymphoid tissues, and must undergo TCR engagement. It has 
394 been demonstrated in solid organ transplantation that alloantigen-specific Tregs provide 
395 higher therapeutic benefits than polyclonal Tregs, without delivering a systemic 
396 immunosuppressive effect.96 Directing Tregs against a specific alloantigen also permits 
397 immunomodulatory functions to be concentrated at the site of the alloantigen source, 
398 circumventing the relative paucity of Tregs. An early study demonstrated that peripheral 
399 Treg expansion in mice could be driven by prolonged low dose subcutaneous infusion of a 
400 specific peptide.97 The induced Tregs had suppressive abilities, and demonstrated high 
401 levels of Foxp3 expression indicating a stable Treg phenotype. However, in IBD, a specific 
402 antigen has yet to be identified.
403
404 The relative paucity of Tregs in peripheral blood represents an obstacle to the development 
405 of a cellular therapy, though the optimum number of Tregs to be infused remains unclear. It 
406 has been suggested that the number of Tregs given should be at least as great as the 
407 number of Teffs in the body,98 though Tregs also exhibit the ability to confer suppressive 
408 ability on conventional T cells through ‘infectious tolerance’.96 In this process, the direct 
409 secretion of TGF-β, IL-10 and IL-35 by Tregs, and indirect induction via DCs, can generate a 
410 regulatory microenvironment which may partially circumvent the problem of low absolute 
411 numbers of Tregs.99
412
413 Several groups have developed protocols in line with GMP requirements to permit ex vivo 
414 cell expansion of Tregs.98,100,101 GMP-manufactured Tregs delivered in some early trials were 
415 only around 50% pure, but the development of plastic beads coated with stimulatory 
416 antibodies and the discovery of additional surface markers for Treg phenotyping mean that 
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417 a product with purity greater than 90% is now achievable.98 Contamination of the expansion 
418 product with Teffs hampers expansion,102 but the inclusion of rapamycin in cell culture 
419 blocks expansion of Teffs without affecting Treg proliferation, leading to the preferential 
420 promotion of Treg proliferation.98,103
421
422 Tregs are first isolated from peripheral blood by surface marker expression 
423 (CD4+CD25hiCD127lo). This can be performed using stream in air fluorescence-activated cell 
424 sorters (FACS) which yield a highly pure starting population, but the necessary air exposure 
425 requires high efficiency particulate air (HEPA) enclosures, and single use sample lines to be 
426 compatible with manufacturing GMP cell products. Closed system magnetic bead-activated 
427 cell sorting (MACS) can be adapted for large-scale isolation of human Tregs, but unlike FACS 
428 cannot easily distinguish surface marker expression density. A recently developed 
429 microfluidic chip fluorescence-activated cell sorter, the MACSQuant Tyto (Miltenyi Biotech, 
430 Germany) surmounts the problems of stream in air sorters, as the cells remain in a closed 
431 system throughout the sorting process. Expansion of the sorted cells is achieved through 
432 polyclonal TCR activation with anti-CD3/anti-CD28 beads.104 Tregs are sampled and checked 
433 for sterility and phenotype throughout the expansion process. With optimised conditions, a 
434 500-fold expansion can be anticipated over a 14 day period.101.
435
436 Uncertainty about the plasticity of Tregs in culture and following infusion means there is a 
437 theoretical concern about the development of a pro-inflammatory phenotype, which could 
438 lead to transplant rejection or aggravation of inflammation. However, rapamycin-expanded 
439 Tregs are not contaminated by IL-17-producing Th17 cells, and these cells maintain a stable 
440 phenotype on transfer in vivo to mice.105 Canavan et al. found that the starting population 
441 for Treg expansion from the peripheral blood of CD patients has a critical effect on the 
442 phenotype of the expanded cell population.100 Tregs from a highly pure FACS-sorted ‘naïve’ 
443 CD4+CD25hiCD127loCD45RA+ precursor population demonstrated enhanced suppressive 
444 ability and reduced Th17 plasticity in vitro compared to a FACS-sorted 
445 CD4+CD25hiCD127loCD45RA- or MACS-enriched CD8-CD25+ population. Rapamycin appears to 
446 imprint a fixed CD4+CD25hi phenotype to cells expanded from a ‘naïve’ CD45RA+ population, 
447 as evidenced by the retention of demethylation at the Foxp3 locus.
448
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449 TREG THERAPY IN OTHER CONDITIONS:
450
451 There is an increasing body of evidence for the use of Tregs as cellular therapy in 
452 autoimmune disease and transplantation (see Table 1). Adoptive transfer of Tregs to 
453 prevent GvHD was the first illustration of the potent therapeutic potential of Tregs in 
454 experimental transplantation. 
455
Study Clinical 
context
Enrichment 
protocol
Expansion 
protocol
Dose Study outcome
Trzonkowski et 
al. (2009)
Treatment of 
acute and 
chronic GvHD
N=2
Tregs from allogenic 
buffy coat. CD4+ 
negative bead 
selection followed by 
FACS-based sorting of 
CD4+CD25hiCD127lo 
cells
RPMI 1640 with 10% 
autologous plasma
IL-2 (1000IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
3 weeks
Acute 
GvHD: 
1x106/kg
Chronic 
GvHD: 
3x106/kg
Transient improvement 
in acute GvHD; 
alleviation of 
symptoms and 
reduction of 
immunosuppression in 
chronic GvHD
Brunstein et al. 
(2011)
Prevention of 
GvHD following 
umbilical cord 
blood 
transplantation
N=23
CD25+ bead positive 
selection
X-Vivo 15 with 10% 
human AB serum
IL-2 (300IU/ml)
Anti-CD3/anti-CD28 
beads (1:2)
18±1 days
0.1-
30x105/kg
Well –tolerated; 
reduced incidence of 
grade II-IV GvHD in 
Treg recipients
Marek-
Trzonkowska 
et al. (2012)
Safety of 
autologous in 
vitro expanded 
Tregs in 
paediatric type 1 
diabetes
N=10
FACS-based sorting of 
CD3+CD4+CD25hiCD127
lo cells
CellGro medium 
with 10% 
autologous plasma
IL-2 (1000IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
Up to 2 weeks
10-
20x106/kg
Well-tolerated; 
decreased insulin 
requirements and C-
peptide levels in Treg 
recipients
Desreumaux et 
al. (2012)
Safety and 
efficacy in 
Crohn’s disease
N=20
Culture of PBMCs with 
ovalbumin, IL-2 and IL-
4 followed by cloning 
of ovalbumin-specific 
T cells
X-Vivo 15
IL-2 (200IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
Ova-Tregs selected 
based on 
ovalbumin-specific 
IL-10 production
12 to 15 weeks
1x106-
1x109
Well-tolerated; dose-
related efficacy 
Bluestone et 
al. (2015)
Safety in adults 
with type 1 
diabetes
(N=14)
FACS-based sorting of 
CD4+CD25hiCD127lo 
cells
X-Vivo 15 with 10% 
human AB serum 
and deuterated 
glucose
IL-2 (300IU/ml)
Anti-CD3/anti-CD28 
beads (1:1)
14 days
0.05x108-
26x108
Well-tolerated, no 
significant adverse 
events. Stable C-
peptide levels and 
insulin use in recipients 
for up to two years 
post infusion
Mathew et al. 
(2018)
Safety in living 
donor kidney 
transplant 
N=9
CliniMACS plus GMP 
enrichment system 
(Miltenyi)
IL-2 (1000IU/ml)
MACS © GMP 
expansion beads 
1:1-4:1
3 weeks
0.5-5x109 Well-tolerated, no 
infections or rejection 
up to two years post 
transplant
456
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457 Table 1: Summary of clinicaltrials.gov listings for reported trials using in vitro expanded 
458 regulatory T cell (Treg) therapy
459
460 Graft vs. host disease (GvHD):
461
462 The risk of developing GvHD following haematopoetic stem cell transplantation (HSCT) is 
463 associated with low numbers of Tregs in the periphery,106 and in vivo expansion of Tregs 
464 post-HSCT using low dose IL-2 has demonstrated efficacy against GvHD.107,108 Studies in mice 
465 involving infusion of cultured CD4+CD25+ T cells resulted in a significantly reduced GvHD 
466 phenotype,109 and in humans it was found that infusion of freshly isolated donor Tregs given 
467 at the same time as haplotype mismatched HSCT prevented the development of GvHD.110 
468 Five trials of ex vivo expanded Tregs have to date involved small numbers of patients only, 
469 but suggest therapy can prevent or delay the onset of chronic GvHD111,112. Treg therapy 
470 seems to be effective only in the chronic form of GvHD, but this may be because of the time 
471 requirements to expand the cellular product which makes it difficult to administer in a 
472 timely manner in acute GvHD.113
473
474 Solid organ transplant:
475
476 Adoptive Treg therapy has been trialled following renal and liver transplantation, with the 
477 aim of inducing tolerance to the allograft and reducing the burden of long-term 
478 immunosuppression.114 Tregs have been shown to control immune responsiveness to 
479 alloantigens and contribute to ‘operational tolerance’ in preclinical transplantation 
480 models.115,116 Recipient-derived Tregs expanded for direct and indirect pathway 
481 allospecificity in vitro were able to mediate effective protection against acute and chronic 
482 rejection in skin and heart allografts in mice,117 and could be used to induce tolerance of a 
483 murine skin transplant following thymectomy and T cell depletion.118 In these models, 
484 alloantigen reactive Tregs were more effective at preventing graft rejection than 
485 polyclonally expanded Tregs104.
486
487 A phase I study in renal transplantation recruited nine living donor transplant recipients, and 
488 used the product of leukapharesis as the basis for ex vivo expansion of polyclonal 
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489 autologous Tregs.114 Alemtuzumab was given at induction to achieve lymphodepletion, on 
490 the basis of previous experiments suggesting a reduction in circulating Teffs worked 
491 synergistically with Treg infusion to prolong allograft survival.116 Recipients were switched 
492 from traditional immunosuppression with tacrolimus, which blocks IL-2 production, to 
493 sirolimus (rapamycin), which has Treg promoting activity.119 
494
495 An enhanced suppressive ability of the expanded Tregs was demonstrated when compared 
496 to Tregs taken directly ex vivo.114 There were no adverse infusion-related side effects, 
497 infections or rejection up to two years post-transplant, and there was a 5-20 fold increase in 
498 the number of circulating Tregs seen up to one year post-transplant. Transplant biopsies 
499 taken at three months did not show rejection and recipients had not developed peripheral 
500 donor-specific antibodies. An additional important outcome from trials in transplantation is 
501 that they have demonstrated that it is possible to expand Tregs from immunocompromised 
502 patients.120
503
504 A trial of Treg immunotherapy in liver transplantation is currently underway.121 This is 
505 predicated on the observation that when liver allografts in mice were infiltrated with Tregs, 
506 loss of Treg numbers was associated with a loss of tolerance.122 Increased frequencies of 
507 Tregs are also seen in human subjects who acquire ‘operational tolerance’ to their liver 
508 transplant.123  
509
510 Type 1 diabetes mellitus:
511
512 The development of T1DM is associated with deficits in the number and suppressive activity 
513 of Tregs.124  Accelerated diabetes onset is seen in both scurfy mice29 and children with 
514 IPEX,125 highlighting the role of Tregs in protecting pancreatic islet cells from destruction. 
515 Tregs have been implicated in the pathogenesis of diabetes in the non-obese diabetic (NOD) 
516 mouse model,126,127 and anti-CD3 antibodies have been efficacious in the treatment of 
517 diabetes in both mouse128,129 and human trials.130,131 Subjects exhibited lower insulin 
518 requirements and higher C-peptide levels at least 18 months after a short course of 
519 intravenous treatment, with evidence of anti-CD3 treatment inducing expansion of a 
520 CD4+CD25+ T cell population.129A trial of ten children treated with expanded polyclonal Tregs 
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521 within two months of their diagnosis demonstrated statistically lower insulin requirements 
522 and C peptide levels compared with matched controls up to six months post infusion, with 
523 two patients remaining insulin-independent.124 There were no serious adverse events up to 
524 one year following infusion. 
525
526 In a phase I open-label trial of 14 adult patients infused with ex vivo expanded Tregs in 
527 escalating doses, 7 of 14 patients had stable C peptide levels and insulin use for up to two 
528 years following infusion.101 However, the study was not powered to detect significant 
529 clinical improvement. There were no infusion reactions or therapy-related serious adverse 
530 events. Phenotypic analysis of the cell product after expansion and after infusion identified 
531 stable surface marker expression, demonstrating that the infused Tregs did not acquire a 
532 pathological phenotype. High throughput TCR-β sequencing analysis indicated that 
533 expanded Tregs retained a high degree of diversity.
534
535 Adoptively transferred Tregs were tagged by labelling the deoxyribose moiety of replicating 
536 DNA during expansion ex vivo, through addition of deuterated [6,6-2H2] glucose to Treg 
537 culture throughout the 14 day expansion period.101 Patient samples were analysed by gas 
538 chromatography mass spectrometry (GC-MS) for deuterium enrichment to create 
539 pharmacokinetic curves. Adoptively transferred T cell numbers peaked at two weeks 
540 following infusion, but were still detectable at up to 25% of the peak level at one year in 
541 peripheral blood. Significantly, deuterium labelling was never found in non-Tregs, indicating 
542 the stability of infused Tregs. However, due to the nature of this study, the stability of these 
543 cells was not assessed within the target tissue.
544
545 TREG THERAPY IN INFLAMMATORY BOWEL DISEASE:
546
547 A local imbalance between Treg and Teff responses plays a key role in the development of 
548 gut inflammation in IBD.8 T cell gut homing is mediated by specific interaction between 
549 integrin α4β7 and its ligand MAdCAM-1.132,133 Several groups have shown that transfer of 
550 Tregs into mice leads to clinical and histological improvement in colitis,14,134,135 and 
551 rapamycin-expanded Tregs ameliorated established colitis in a SCID mouse model.136 
552 Polyclonality of the TCR is likely to be an important requirement for Tregs to maintain 
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553 intestinal homeostasis in vivo. Mice which express a restricted TCR repertoire develop 
554 spontaneous colitis due to a loss of tolerance to intestinal microbiota.137
555
556 Several groups have demonstrated that it is feasible to extract Tregs from patients, and 
557 expand them in vitro under GMP conditions, including from subjects receiving thiopurines 
558 and anti-TNFα medications.98,100,103,138 Even after prolonged culture, these Tregs maintained 
559 Foxp3 expression and demonstrated enhanced suppression of autologous T cells. 
560 Uncertainty regarding the potential for adoptively transferred Tregs to express IL-17 and 
561 exacerbate CD lesions is a concern. However, the administration of pro-inflammatory 
562 cytokines (IL-1, IL-2, IL-6, IL-21, IL-21 and TGF-β) failed to induce IL-17 production by 
563 CD45RA+ expanded Tregs in vitro.100
564
565 Antigen specific vs. polyclonal Treg cell products for Crohn’s disease:
566
567 No antigens have yet been verified as causal in CD. Attempts have been made to identify 
568 shared TCRs between CD sufferers with the aim of discovering target antigens.139–141 This 
569 work has observed that the CD4 TCR repertoires are significantly more diverse in patients 
570 with CD and UC than healthy controls.142 This may be explained by GI barrier disruption 
571 increasing the number of antigen presentation events in comparison to a healthy gut. 
572 Resolving a target from the GI peptidome is challenging due to the heterogenous nature of 
573 the environment. Developments in the understanding of non-conventional epitopes are also 
574 increasing the magnitude and complexity of the peptidome itself.143 In the absence of a 
575 known target, the broad reactivity of a polyclonal Treg product may be advantageous, as the 
576 cell product will recognise millions of putative epitopes, increasing the likelihood of TCR 
577 engagement and subsequent Treg activation.  Sequencing of isolated Tregs from GI biopsies 
578 post transfer may yield novel targets, upon which chimeric antigen receptor technology 
579 could be readily implemented.144 
580
581 For Treg therapy to be effective in IBD, expanded Tregs must have the ability to home to the 
582 gut.145 A French group reported the results of an open label multicentre phase I/IIa trial of 
583 ovalbumin-specific Tregs in 20 patients with refractory CD.146 Ovalbumin is a common food 
584 antigen, and is not implicated in intestinal inflammation in animal models or in patients with 
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585 CD. Its distribution along the digestive tract can be used to activate Tregs locally. In the 
586 study, this was facilitated through ingestion of meringue cakes by subjects.146
587
588 The cell product was cultured in the presence of ovalbumin, and trial subjects received a 
589 dose of 106-109 Tregs.146 Patients enrolled in the study had at least moderately active CD, 
590 with a Crohn’s Disease Activity Index (CDAI) greater than or equal to 220 within six months 
591 of screening, and a washout period was required for immunosuppression and anti-TNFα 
592 therapy. The infusion was well tolerated, with mild GI symptoms and CD flares being the 
593 most commonly reported adverse effects. Two patients experienced thrombotic events, but 
594 these are known to occur more frequently in inflammatory conditions including active CD.147 
595 Eight (40%) patients had a significant CDAI response at weeks five and eight after treatment, 
596 with two patients experiencing sustained remission. Overall, the results suggested good 
597 tolerability in this disease group with possible signals of efficacy.
598
599 In the absence of a known antigen, other methods must be used to direct the Tregs to the 
600 areas of inflammation. A recent study has shown that a highly specific retinoic acid receptor 
601 α (RARα) agonist induces expression of Integrin α4β7 (the ligand of MAdCAM-1) on the Treg 
602 surface. Adoptive transfer of RARα agonist-treated Tregs leads to improved Treg trafficking 
603 to gut tissue in a humanised mouse model of colitis.100 Supporting this mechanism for 
604 resolving inflammation, another group have demonstrated that DCs can be engineered de 
605 novo to produce high concentrations of RA.148 When transferred to mice, the RA-secreting 
606 DCs were able to augment the expression of Foxp3 and the gut-homing receptor CCR9 in 
607 native Tregs with the subsequent suppression of colitis. 
608
609 The RARα agonist treated cell product forms the basis of the TRIBUTE trial (ClinicalTrials.gov 
610 Identifier: NCT03185000), a double-blinded placebo-controlled phase I/IIa trial of adoptive 
611 Treg therapy in CD.
612
613 FUTURE DEVELOPMENTS IN TREG THERAPY:
614
615 The potential therapeutic benefits of adoptive cell therapy are being explored in numerous 
616 autoimmune conditions. In SLE, adoptive transfer of ex vivo expanded Tregs in mice delayed 
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617 the onset of renal complications and prolonged survival,149,150 and a pilot study of low dose 
618 IL-2 in 37 patients led to increased circulating peripheral Treg numbers and decreased SLE 
619 disease activity scores.151 Adoptive Treg transfer in a single patient with cutaneous lupus did 
620 not lead to clinical benefit, but increased percentages of highly activated Tregs were 
621 identified in biopsies taken from diseased skin.152 Treg accumulation in skin was associated 
622 with a marked attenuation of IFN-, which was more pronounced relative to peripheral 
623 blood. 
624
625 Preliminary results from mouse models suggest a role for Treg therapy in conditions as 
626 diverse as pemphigus vulgaris,153 autoimmune hepatitis,154 multiple sclerosis,113 asthma, 
627 and allergy, in which antigen-specific Tregs may represent a viable therapeutic option.155,156
628
629 Many ongoing challenges exist for the advancement of Treg therapy. Uncertainties remain 
630 about the optimal timing of ex vivo Treg expansion, and whether IL-2 administration would 
631 be a useful adjunct to support a Treg population in vivo.101,107 In addition, concomitant 
632 treatment of autoimmune disease with immunosuppressive drugs may affect the function 
633 of adoptively transferred cells.95 
634
635 The optimal dosing strategy for Treg therapy also r mains unclear, although data tracking 
636 the survival of deuterium-labelled Tregs in vivo could be invaluable in informing a suitable 
637 dosing regimen.101 A two-phase decay in numbers of deuterium-labelled Tregs has been 
638 seen, with 75% of the peak level lost at three months. However, levels stabilised at one 
639 year, with up to 25% of peak Treg numbers remaining in the peripheral circulation.  The 
640 decrease in labelled Tregs may represent cell death, trafficking to lymphoid tissue and sites 
641 of inflammation, or proliferation of the Treg compartment leading to dilution of deuterium 
642 enrichment. Reassuringly, at no point during the trial was deuterium detected in cell 
643 populations other than Tregs, suggesting a stable phenotype in vivo.101 
644
645 Tracking of TCR clonotypes may also provide useful data on Treg kinetics and dispersal. 
646 Analysis of the TCR repertoire has suggested that the kinetics of transferred Tregs in 
647 peripheral blood varies significantly between individuals157. In a descriptive study, the TCR 
648 Vα chain was sequenced in two patients receiving donor Treg infusion157. Treg therapy 
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649 altered the patients’ peripheral TCR repertoire considerably towards that of the infused cell 
650 product, but to different degrees in each patient. Importantly, the degree of alteration of 
651 the TCR repertoire appeared to correlate with clinical response. This suggests that 
652 monitoring TCR repertoires following adoptive cell transfer may provide clinically 
653 meaningful information.
654
655
656 CONCLUSION:
657
658 There is now robust evidence of the therapeutic potential of Treg therapy in Crohn’s 
659 disease. Trials in multiple autoimmune diseases and results from use of ovalbumin-specific 
660 Tregs in IBD show promising early signs of efficacy. The safety signal is reassuring, with 
661 evidence that the adoptively transferred Treg phenotype is stable in vivo. Results from 
662 deuterium labelling suggest that infused Tregs may be able to exert a long-lasting systemic 
663 effect with labelled cells detectable up to a year after infusion. It is hoped that upcoming 
664 early phase clinical trials in patients with Crohn’s disease will inform safety, dosing, and Treg 
665 kinetics and dispersal allowing further development of a novel therapeutic option in this 
666 hard-to-treat population. 
667
668 FIGURE LEGEND:
669
670 Figure 1. Mechanisms of Treg mediated suppression
671 Tregs utilize a multitude of mechanisms to promote a tolerogenic microenvironment and 
672 tissue repair. (A) Secretion of the anti-inflammatory cytokines, IL-10, TGF-β and IL-35, not 
673 only inhibit Teff proliferation, but also suppress Th1 and Th17 effector function, both of 
674 which are key mediators of IBD. (B) Tregs express the high affinity IL-2 receptor -chain 
675 (CD25) consuming local IL-2 with greater affinity than effector cells. Teffs which are ‘starved’ 
676 of IL-2 exhibit restricted proliferation and undergo apoptosis. (C) Tregs co-expressing CD39 
677 and CD73 disrupt metabolic processes in effector cells by converting ATP into peri-cellular 
678 adenosine, a potent inhibitor of Teff function. Additionally, adenosine stimulates TGF- 
679 production, promoting development of pTregs. (D) Tregs are capable of secreting perforin, 
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680 granzyme B and galectin-1 which are directly cytotoxic against Teffs. Activated Tregs also 
681 express TRAIL, inducing apoptosis of Teffs through the TRAIL/DR5 pathway. (E) Expression of 
682 CTLA-4 degrades DC-derived CD80 and CD86 leading to impaired CD28-mediated co-
683 stimulation of T cells. DC function is further inhibited through the interaction of Treg-
684 derived TIGIT and CD155 on DCs. This induces IL-10 production and suppresses IL-12. (F) In 
685 response to alarmins, Tregs produce AREG, an important regulator of tissue repair and 
686 regeneration. AREG, amphiregulin; ATP, adenosine tri-phosphate; CTLA-4, cytotoxic T 
687 lymphocyte associated protein 4; DC, dendritic cell; DR5, death receptor 5; IBD, 
688 inflammatory bowel disease; pTregs, peripheral regulatory T cells; Teff, T effector 
689 lymphocyte; TGF-, transforming growth factor beta; Th1, T helper 1 cell; Th17, T helper 17 
690 cell; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TRAIL, TNF-related apoptosis-
691 inducing ligand; Treg, regulatory T cell. Figure generated using BioRender© illustration 
692 software.
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